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Abstract
Summary Cost-effectiveness analysis of FRAX® intervention thresholds (ITs) in Singaporean women > 50 years of age showed
that generic alendronate was cost-effective at age-dependent major osteoporotic fracture (MOF) IT from the ages of 65 years for
both full and real-world adherence whilst hip fracture (HF) ITs were cost-effective from the ages of 60 and 65 years. Alendronate
was cost-effective irrespective of age only at fixed MOF IT of 14% and HF IT of 3.5%.
Introduction FRAX®-based intervention thresholds (ITs) were recently identified for osteoporosis management in Singapore.
This study aimed to assess the cost-effectiveness of ITs in Singaporean women over the age of 50 years.
Methods A validated Markov microsimulation model was used to estimate the lifetime healthcare costs (SGD2019) per quality-
adjusted life-years (QALY) of generic alendronate compared with no treatment. Cost-effectiveness of age-dependent FRAX®
major osteoporotic fracture (MOF) and hip fracture (HF) ITs was explored. In addition, ITs that would lead to cost-effectiveness
were computed. Fracture incidence and cost data were obtained from the Ministry of Health and a previously published
Singaporean study. A cost-effectiveness threshold of SGD 62,500/QALY gained was used, based conservatively on 0.7 times
the Singapore GDP per capita.
Results Generic alendronate was shown to be cost-effective at MOF ITs from the ages of 65 years, while HF ITs were cost-
effective from the ages of 60 and 65 years, assuming full and real-world adherence, respectively. A 14%MOF and a 3.5%HF ITs
were required for alendronate to be cost-effective above 50 years.
Conclusion This study suggests that the treatment of Singaporean women with alendronate is cost-effective at age-dependant
FRAX® intervention thresholds at 65 years and older. Furthermore, identifying women at any age above 50 years with a 10-year
risk of MOF or HF of 14% or 3.5% would lead to efficient use of resources. Cost-effective access to therapy for patients at high
fracture probability based on FRAX® could contribute to reduce the growing burden of osteoporotic fractures in Singapore.
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Introduction
The burden of osteoporosis and its dreaded consequence of
fragility fractures is expected to increase worldwide as
populations age. It is estimated that the number of individ-
uals at risk for such fractures worldwide is going to in-
crease two-fold from the 158 million it was in 2010 to
319 million in 2040 [1]. Nowhere is this grave projection
going to hold more true than in Asia, which is home to 4.5
billion people. The population in Asia aged over 65 years
is projected to more than quadruple by 2050, and to further
grow by almost six-fold by the year 2100 [2]. It is predict-
ed that by 2050, over half of the world’s hip fractures will
occur in Asia [3], and this will come at great cost; treating a
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Pacific’s regional per head gross domestic product (GDP)
each year currently [4].
Singapore is an island nation in SE Asia. It is a developed
economy with a total population of 5.4 million and a GDP per
capita of SGD 89,000 (~ USD62,900) [5]. Healthcare in
Singapore is under the responsibility of the Singapore
Government’s Ministry of Health (MOH). Healthcare is kept
affordable for Singaporeans through heavy government sub-
sidies, supplemented by national insurance schemes and en-
dowment funds such as Medisave, MediShield, Community
Health Assist Scheme (CHAS), Medifund and ElderShield
(https://www.moh.gov.sg/cost-financing/healthcare-schemes-
subsidies).
Singapore too is facing the problem of increasing burden of
osteoporosis and related fractures. In 2017, the incidence of
osteoporotic fractures was estimated at 15,267 cases. By the
year 2035, the number of incident fractures is projected to
increase by 58% to 24,104 cases [6]. Increase in healthcare
expenditure for osteoporosis in general is driven by the costs
of treatment, making up 70% of the total costs [7]. In addition
to the financial costs associated with the treatment of osteopo-
rosis and osteoporotic fractures, the associated morbidity as
well as the excess mortality associated with osteoporotic frac-
tures have a major impact on quality of life, both immediately
afterwards and in the long term [8, 9]. Singapore also has one
of the most rapidly ageing populations in the Asia Pacific [10].
As a consequence, without targeted interventions, the eco-
nomic burden of fragility fractures to the Singapore healthcare
system is predicted to substantially increase in the coming
decades [6]. The overall costs (including both direct and indi-
rect) of incident fractures in Singapore were estimated at S$
183.5 million in 2017, and it is forecasted to increase by
57.8% to S$ 289.6 million by 2035 [6].
Many regulatory agencies, governmental health bodies
and osteoporosis societies worldwide have adopted inter-
vention thresholds (ITs) based on densitometric T-scores.
However, prospective epidemiological studies have
shown that most osteoporotic fractures occur in individ-
uals with a BMD T-score in the osteopenic or even nor-
mal range [11, 12]. Various fracture risk assessment tools
that take into account a constellation of risk factors other
than just BMD alone exist [13]. A strategy that incorpo-
rates clinical risk factors into the decision-making process
may help identify patients who would have been other-
wise missed and precluded from being offered treatment
as well as serve to avoid treatment in low-risk individuals.
The FRAX ® algorithm (http://www.shef.ac.uk/FRAX) is
one such risk assessment tool. It was calibrated for
Singapore-specific fracture risk and mortality rates in
2010. ITs based upon probabilities of major osteoporotic
(MOF) and hip fractures (HF) using the FRAX® algo-
rithm have been implemented in several countries [14].
Due to the vast heterogeneity in epidemiologic and
economic characteristics between countries, intervention
thresholds should be country specific. In the USA, a HF
IT of 3% and a MOF IT of 20% were deemed as cost-
effective [15], while MOF ITs of 7% and 15% were found
to be cost-effective in the UK [16] and Switzerland, re-
spectively [17]. Cost-effectiveness analyses can be espe-
cially useful to assess and guarantee the economic value
of ITs in osteoporosis and have employed two different
approaches. One way is to determine the cost-
effectiveness of existing ITs derived by other methods;
the other is to determine MOF or HF probabilities at
which intervention becomes cost-effective [17].
FRAX ®-based age-dependent mean-weighted MOF and
HF ITs for post-menopausal Singaporean women were iden-
tified in 2018 [18]. These ITs were derived using a transla-
tional approach which is similar to that employed by the
National Osteoporosis Guideline Group (NOGG) in the UK
[16, 19]. These intervention thresholds are age-specific and
based on the principle that treatment is indicated for a woman
if her probabilities for MOF and/or HF exceed that of a similar
age woman with a history of a fragility fracture. However,
economic evaluation of these thresholds and whether they
are cost-effective have not been performed. Assessment of
the economic value of such intervention thresholds is impor-
tant for policymakers to know before recommendations for
their implementation can be made.
Amongst the anti-osteoporosis agents currently available,
the amino-bisphosphonates are the most widely used since
they have demonstrated significant anti-fracture efficacy at
vertebral, non-vertebral and hip sites [20]. Alendronate was
the first commerciallymarketed amino-bisphosphonate for the
treatment of osteoporosis and, consequently, the first to lose
its patent and be provided to the market as a generic drug.
After its introduction, generic alendronate was widely adopted
by all payees in Singapore, owing to its lower price compared
with branded alendronate and is the most frequently pre-
scribed anti-osteoporosis agent in Singapore [6].
The purpose of our study was thus to explore the cost-
effectiveness of using generic alendronate compared with no
treatment at different age-dependent FRAX® MOF and HF
ITs in Singaporean women older than 50 years of age.We also
aimed to determine the FRAX® calculated fracture probabil-
ities at which therapeutic intervention with generic
alendronate would become cost-effective in this population.
Methods
Model structure
A previously validated Markov microsimulation model [21,
22] was adapted to the Singaporean healthcare context to es-
timate the cost-effectiveness of alendronate under different
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ITs. Subjects initiate the model in the state “no fracture” and
can transit between fracture health states (hip, vertebral, wrist
and other fracture), their corresponding post-fracture states
and death, along a 6-month cycle. Quality-adjusted life-years
(QALY) that take into consideration quality of life as well as
life-years was used to measure health effects. The Markov
model captures both healthcare costs and QALY over a life-
time. The discount rates of 3% used for costs and QALY are in
line with the Agency for Care Effectiveness (ACE) guidelines
for economic evaluation in Singapore [23]. The model was
built using TreeAge Pro 2020 (TreeAge Pro Inc.,
Williamston, MA, USA) and adheres to the recent recommen-
dations for the conduct of economic evaluations in osteopo-
rosis [24]. Figure 1 presents the model structure, and data used
for the model are shown in Table 1.
Fracture risk
Baseline age-specific hip fracture, wrist fracture and other
fracture (humerus, forearm and femur) incidences for the
years 2015–2017 were obtained from the Singapore
Ministry of Health (MOH) Central Claims Processing
System that covers all admissions and emergency room visits
to public and private acute and community hospitals in
Singapore. For hip fractures, data on inpatient admissions of
Singapore residents with a discharge diagnosis of fracture in-
volving the neck or the intracapsular, upper epiphyseal,
subcapital, cervical, trochanteric, or subtrochanteric areas
were used. This data which had been retrieved using the fol-
lowing diagnostic codes from the International Classification
of Disease, Tenth revision, Australian version (ICD-10-AM):
S7200, S7201-S7211, S722-S723, was published in 2018
[25].
TheMOH database captures only severe vertebral fractures
that require hospitalization and/or emergency room visits and
might not have captured less severe vertebral fractures.
Therefore, the ratio between vertebral and hip fracture inci-
dence obtained from a study by Chandran et al. was applied to
derive vertebral fracture incidence [6].
Initial fracture probabilities were then adjusted to reflect the
fracture risk in the target population in comparisonwith that of
the general population. To determine 10-year MOF and HF
probabilities, each age-specific fracture probability (i.e. hip,
wrist, vertebral and other) was multiplied by a relative risk
(RR). This method has been described previously by
Tosteson et al. [15]. In the original FRAX® MOF probabili-
ties derivation, only hip, clinical vertebral, wrist and humerus
fracture are included. Since “other” fractures in our data set
inc luded f rac tures a t o ther s i tes in addi t ion to
humerus fractures, when estimating the RR needed to get a
Fig. 1 a FRAX® intervention thresholds tested in the model. b Graphical representation of the model. c Results and interpretation
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pre-definedMOF IT, we only considered humerus fractures in
the calculation; the latter constituted 29.5% of “other frac-
tures” in our data set.
Fracture risk was also adjusted in the model when a new
fracture occurred during the simulation process, as has been
previously done [21]. The model incorporates, during the sim-
ulation process, an increased risk of subsequent fracture for
individuals who have a prior fracture at the same location.
These increased relative risks are 4.4 (3.6, 5.4), 2.3 (1.5,
3.7), 3.3 (2.0, 5.3) and 1.9 (1.7, 2.2) for vertebral, hip, wrist
and other fractures, respectively [26]. As the underlying risk
of fracture may contain prior fracture at other sites and a mul-
tiplicative hypothesis cannot be supported at this time, we
conservatively did not model an increased risk of subsequent
fractures at sites different from that of the prior fracture(s),
except in the year following the fracture. However, an in-
creased relative risk of 2.3 (2.0, 2.8) is modelled for a hip
fracture after a vertebral fracture, because this effect is largely
supported by the literature [26]. Since the increased risk after a
fracture is shown to decrease with increasing age, we reduced
the RR by 10% per each decade above the age of 70 years [27,
28]. Subsequent fractures of the same type are assumed to
have no additional effect because of the absence of data pro-
viding an accurate relationship between the number of prior
fractures and an increased risk.
Baseline mortality data for the general women population
was derived from the Singapore’s Department of Statistics
[29]. An increased mortality after hip fracture and vertebral
fracture was assumed in line with previous studies [22].
Because excess mortality may also be attributable to
Table 1 Incidence of fractures, costs, utilities and treatment effects used in the model
Parameter
Incidence of fracture (rate/100)
Hip 0.011 (50–54 y), 0.027 (55–59 y), 0.070 (60–64 y), 0.157 (65–69 y), 0.334 (70–74 y), 0.694 (75–79 y), 1.116 (80–84
y), 1.973 (85+)
Vertebral 0.013 (50–54 y), 0.032 (55–59 y), 0.083 (60–64 y), 0.186 (65–69 y), 0.396 (70–74 y), 0.825 (75–79 y), 1.323
(80–84 y), 2.338 (85+)
Wrist 0.056 (50–54 y), 0.105 (55–59 y), 0.151 (60–64 y), 0.179 (65–69 y), 0.193 (70–74 y), 0.258 (75–79 y), 0.324
(80–84 y), 0.342 (85+), 0.072 (50–54 y), 0.137 (55–59 y), 0.171 (60–64 y), 0.240 (65–69 y), 0.366 (70–74 y),
0.520 (75–79 y), 0.670 (80–84 y), 0.913 (85+)
Other 0.072 (50–54 y), 0.137 (55–59 y), 0.171 (60–64 y), 0.240 (65–69 y), 0.366 (70–74 y), 0.520 (75–79 y), 0.670
(80–84 y), 0.913 (85+)
Fracture costs (SGD2019)
Hip, first 6 months 28,823
Hip, yearly long term 2500
Vertebral, first 6 months 18,937
Wrist, first 6 months 15,718
Other, first 6 months 17,924
Health state utility values


















Drug costs (per year)
Clinic visit SGD 200
BMD measurement SGD 180
RR relative risk
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comorbidities, we assumed that only 25% of the excess mor-
tality following fractures was attributable to the fractures
themselves [30]..
Fracture cost
The healthcare payer perspective was used for the cost esti-
mation in line with the ACE guidelines for health economic
evaluation in Singapore [23]. All costs were obtained from
administrative data of the Ministry of Health, were expressed
in SGD 2019 and adjusted using the current inflation rates.
Short-term fracture costs included that for admission for the
index fracture, emergency department costs and 6-month
post-fracture care such as post-operative follow-up and com-
munity hospital costs incurred after discharge. Long-term
costs for hip fracture included outpatient visits and nursing
home costs. Nursing home placement rates post-hip fracture
are low in Singapore with only 2.7% of women aged 65 and
older per year admitted to such long-term care. The direct cost
of hip fracture was estimated to be SGD 28,823. The costs of
wrist and other fractures were also derived from the same
database and estimated at SGD 15,718 and SGD 17,924, re-
spectively. The cost for vertebral fractures was derived from
Chandran et al. [6], and was estimated to be SGD 5312. Hip
fractures were further associated with yearly long-term costs
of SGD 2,500.
Utility values
In the absence of utility data for osteoporosis and osteoporotic
fractures in Singapore, the effects of fractures on utility were
derived from the International Costs and Utilities Related to
Osteoporotic Fractures Study (ICUROS) study [31]. ICUROS
is a large study that assessed the quality of life post-fracture of
patients from 11 countries and included 2808 patients. Since
fractures other than hip, clinical vertebral and wrist were not
included in the ICUROS study, we used estimates from a
previous systematic review [32]. Baseline utility data were
assumed to be similar to that of US women [33]. Additional
utility loss following multiple fractures was also modelled
using previous studies [21].
Strategies
Three treatment strategies over a 5-year period were simulated
in the model: (i) alendronate with full adherence, (ii)
alendronate with real-world adherence levels and (iii) no treat-
ment. To maintain comparability between the current analysis
and other studies that have assumed full adherence [34] with
oral bisphosphonates, an initial strategy assuming full adher-
ence was conducted. An earlier published study of ours had
demonstrated excellent compliance rates to oral bisphospho-
nate therapy at 2 years amongst patients recruited into the
nationwide secondary fracture prevention program in
Singapore- OPTIMAL [35]. However, the situation is quite
different in ordinary clinical practice with adherence to these
agents reported to be suboptimal. This can have substantial
consequences on cost-effectiveness [36], and therefore, a
strategy assuming real-world adherence with alendronate
was also assessed.
To determine the effect of alendronate on fracture risk, a
recent network meta-analysis of pooled data for oral
bisphosphonates conducted by the National Institute for
Clinical Excellence in the UK was used [37]. This study sug-
gests that oral bisphosphonates have a RR of 0.45 for vertebral
fracture, a RR of 0.67 for hip fracture and an RR of 0.81 for
wrist fracture and other fractures. After stopping alendronate,
a linear decrease of the effects for a duration similar to the
duration of therapy was assumed, in line with previous eco-
nomic analyses of oral bisphosphonates [38] and clinical data
[39].
To model a real-life scenario with alendronate, we used a
similar methodology as that has been used previously that
focused on medication persistence. Persistence has been
shown to have the most influence on cost-effectiveness [40].
Real-world persistence data with oral bisphosphonates were
derived from a recent systematic review suggesting that the
mean persistence was 53% at 6 months, 46% at 1 year, 37% at
2 years and 31% at 3 years [41]. For patients who stopped
taking their therapy, the treatment cost immediately stopped
and the offset (assumed as a period similar to duration on
therapy) period started at the same time. For those who
discontinued therapy within 6 months, no treatment effect
was assumed, since at least 6 months of treatment is necessary
to reduce the risk of fractures.
Treatment costs including medication costs, cost of follow-
up visits at outpatient clinics, and bone density measurement
were obtained from pre-subsidy charges at public healthcare
institutions from the Ministry of Health. In accordance with
the usual clinical practice in Singapore, it was assumed that
there would be 2 clinic visits in the first 1 year followed by 1
visit annually in subsequent years. Each clinic visit costs SGD
200. The cost of one BMD measurement (SGD 180) using
axial DXA scanning per year was also included.
Gastrointestinal adverse events observed with oral
bisphosphonates have been noted to be generally mild and
transient in our patients. The cost and quality of life impact
of these adverse events would thus only be minor and not
affect the results and were therefore not included in the
analysis.
Analyses
Under this microsimulation model, a total of 1,000,000 of
individual patient simulations were run for each analysis.
Total healthcare costs and accumulated QALYs were
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estimated for each treatment strategy. The incremental cost-
effectiveness ratio (ICER) was then calculated for alendronate
considering both full and real-world adherence compared with
no treatment. ICER was defined as the difference between the
active treatment and the comparator treatment in terms of total
costs (expressed in SGD2019) divided by the difference be-
tween them in terms of QALYs. If the ICER is above a cost-
effectiveness threshold (representing the decision makers’
willingness to pay), then the cost is too high for the benefits,
and the intervention is not considered as cost-effective at the
selected IT.
There is no agreed willingness-to-pay threshold for
adopting health technologies in Singapore. While the thresh-
old of one GDP per capita as recommended by the World
Health Organization (WHO) is commonly used in publica-
tions [42], countries with explicit thresholds have adopted
more stringent levels, with the thresholds of £20,000/QALY
and £30,000/QALY used by UK’s Health Technology
Agency corresponding to 0.70 and 1.04 times of UK’s GDP
in 2015. For our base analysis, we used a stringent threshold
with SGD 62,500 equivalent to 0.7 of Singapore’s GDP per
capita of SGD 89,000 in 2019.
FRAX®-based intervention thresholds
In this current economic study, the cost (SGD) per QALY
gained of generic alendronate compared with no treatment at
different FRAX®-based age-dependent mean-weighted MOF
and HF ITs obtained through the translational approach de-
scribed earlier [18] was assessed. At each age and at the cor-
responding FRAX® MOF and HF IT values, the ICER was
derived. In addition, we also determined the MOF and HF ITs
at which treatment with generic alendronate comparedwith no
treatment became cost-effective using a cost-effectiveness
threshold of SGD 62,500.
Sensitivity analysis
Two sensitivity analyseswere conducted, one with a less strin-
gent cost-effectiveness threshold (i.e. SGD 89,000 corre-
sponding to 1× GDP) and one assuming reduced monitoring
with only one BMD measurement every 2 years instead of
annually and only one visit per year.
Results
The cost (SGD) per QALY gained of alendronate compared
with no treatment at different age-dependent MOF interven-
tion thresholds in Singapore is shown in Table 2. Alendronate
was shown to be cost-effective (i.e. ICER < SGD62,500 per
QALY gained) at MOF IT from the age of 65 years, at both
full adherence and real-world adherence levels. The cost
(SGD) per QALY gained of alendronate compared with no
treatment at different age-dependent hip fracture intervention
thresholds in Singapore is shown in Table 2. Alendronate was
cost-effective at HF IT from the ages of 60 and 65 years,
assuming full adherence and real-world adherence levels, re-
spectively. Intervention with alendronate (in a scenario in-
volving full adherence) was cost-saving at ages 80 years and
above.
Assuming real-world adherence for alendronate (Fig. 2), a
MOF IT of 14% resulted in a cost per QALY gained below
cost-effectiveness threshold of SGD 62,500 at all ages.
Assuming real-world adherence for alendronate (Fig. 3), a
HF IT of 3.5% resulted in a cost per QALYgained below cost-
effectiveness threshold of SGD 62,500 at all ages.
On the sensitivity analysis, it was found that the cost per
QALY gained decreased, with lesser frequency of clinic visits
and DXA scanning. Under this scenario, alendronate was
cost-effective (i.e. ICER < SGD 62,500 per QALY gained)
at MOF ITs from the ages of 60 and 65 years, assuming full
adherence and real-world adherence levels, respectively
(Table 3). For HF IT, alendronate was cost-effective from
the age of 60 years in both adherence scenarios. Cost-saving
was seen for HF ITs under both full and real-world adherence
scenarios from the age of 75 years and for full adherence for
MOF ITs from the age of 80 years (Table 3). Under this
sensitivity analysis, a MOF IT of 12% and a HF IT of 3% lead
to cost-effectiveness results for generic alendronate for the
entire age range.
Assuming a threshold of SGD 89,000 per QALY gained
(i.e. 1× GDP), age-dependant MOF and HIP ITs were cost-
effective from the age of 60 to 65 years, respectively, with
both full and real-world adherence. Using this cost-
effectiveness threshold, generic alendronate was cost-
effective with at a MOF IT of 13% and a Hip fracture IT of
3% for the entire age range.
Discussion
Our study shows that interventions aimed at reducing fracture
risk in osteoporotic patients can be implemented in a cost-
effective manner in Singaporean women at high risk of frac-
ture, at FRAX® MOF and HF ITs of 14% and 3.5% respec-
tively; i.e. treating with generic alendronate can be considered
as cost-effective in Singapore when the 10-year probability of
a MOF equals or exceeds 14% or when the similar probability
of a HF exceeds 3.5% and above. On the other hand, using the
translational approach, it appears that prescription of generic
alendronate for Singaporean women is cost-effective at age-
dependent ITs from the age of 65 years for both MOF and HF
assuming real-world adherence and from 65 years for MOF
and 60 years for HF assuming full adherence.
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The MOF fixed IT of 14% in women over the age of
50, obtained from the cost-effectiveness approach in our
study, was approximately the same as was seen in
Switzerland [17] of 13.8%. Our IT for HF of 3.5% was
lower than the 7% noted in a study from Taiwan [43] and
slightly higher than the 3% denoted as cost-effective in
the USA [15]. The reasons for these differences could
include the variations in the risk of osteoporotic fractures
between countries, the methodology used for epidemio-
logical studies on fractures and for cost-effectiveness anal-
yses and in WTP which varies with the GDP in different
countries.
Table 2 Incremental cost-effectiveness ratio (expressed in costs (SGD) per QALY gained) of alendronate compared with no treatment at different
major osteoporotic fracture intervention thresholds (MOF ITs) and hip fracture intervention thresholds (HF ITs) in Singapore
2(a)Years -MOF ITs Alendronate 
 Full Adherence 
Costs (SGD) per QALY 
gained 
Alendronate  
Real World Adherence 
Costs (SGD) per QALY 
gained 
50 years-2.86% 307,248 392,553 
55 years-4.84% 175,170 338,025 
60 years-8.09% 63,960 113,431 
65 years-13.01% 30,976 57,251 
70 years-18.37% 13,231 27,396 
75 years-23.98% 3,753 11,745 
80 years-26.07% 1,679 10,117 
2(b) Years -HF ITs Alendronate Full Adherence  
Costs (SGD) per QALY 
gained 
Alendronate  
Real World Adherence 
Costs (SGD) per QALY 
gained 
50 years-0.61% 154,635 252,565 
55 year-1.16% 92,689 162,051 
60 years-2.32% 46,876 69,560 
65 years-4.27% 23,910 43,911 
70 years-6.79% 10,237 22,322 
75 years-9.46% 957 8,456 
80 years-12.65% Cost-saving 3,858 
Colour code: white, cost-saving (therapy costs lower than saved fracture costs due to drug effectiveness); light grey, below cost-effectiveness threshold
(SD 62,500/QALY gained); dark grey: not cost-effective (i.e. above cost-effectiveness threshold)
The exchange rate between SGD and USD is 1 USD equals 0.71 SGD as of April 30, 2020
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The National Institute for Health and Care Excellence
(NICE) of UK’s updated multiple technology appraisal
(MTA) on bisphosphonate use in osteoporosis concluded that
generic oral bisphosphonates were cost-effective for people
with even a 1% major osteoporotic fracture risk [37]. The
recommendations made in this appraisal have been criticized
for their clinical inappropriateness [44] and contradict that
found in our study, in which cost-effectiveness was seen only
at much higher intervention thresholds. This is not surprising
given that the total costs of treatment including costs of clinic
visits and DXA scanning are much higher in Singapore than in
the UK.
Branded alendronate was used for the cost-effectiveness
analysis study in Switzerland [17] unlike in ours where the
cost-effectiveness of generic alendronate was explored.
However, age-dependent intervention thresholds were cost-
effective only at older ages in both countries with the thresh-
old being cost-effective from the age of 60 in Swiss women
and from the age of 65 in Singapore. This is likely because the
total costs of treatment are likely similar in our countries with
the cost of BMD monitoring and clinic visits being very high
in Singapore. This likely outweighs the financial benefit of
generic alendronate.
In the sensitivity analysis in our study, when less fre-
quent clinic visits and DXA scanning were factored in,
the MOF and HF ITs decreased, but only slightly to
12% and 3%. A less stringent cost-effectiveness threshold
of SGD 89,000 (the GDP per capita of Singapore) also
lowered the cost-effective MOF and HF ITs slightly to
13% and 3%, respectively.
Our findings pertain to the use of only generic alendronate.
Generic alendronate was chosen for our study as it is the most
frequently prescribed anti-osteoporosis agent in Singapore
currently. It is possible that more effective, albeit
costlier agents may prevent more fractures in higher risk peo-
ple. This might result in more cost-savings and a net increase
Fig. 2 Cost per QALY gained of
full and real-world adherence
with alendronate compared to no
treatment in women with a 14%
risk of MOF at all ages
Fig. 3 Cost per QALLY gained
of full and real-world adherence
with alendronate compared to no
treatment in women with a 3.5%
risk of HFP at all ages
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in QALYs than what was seen with the current scenario with
generic alendronate. Other antiosteoporosis medications, such
as branded alendronate, risedronate, raloxifene, zoledronic ac-
id (given as an annual intravenous infusion), teriparatide (giv-
en as a daily subcutaneous injection) and denosumab (admin-
istered as a subcutaneous injection once in 6 months), are also
available in Singapore. Though direct head-to-head compari-
sons are lacking, there exists some data to suggest that agents
such as Zoledronic acid and Denosumab may be more effica-
cious at reducing fracture risk than alendronate [37]. From a
purely economic perspective, the cost-effectiveness of each
treatment would differ, and each medication would have a
different cost-effective threshold to intervene with at.
However, to deprive a patient of a certain medication unless
she attains the threshold that is needed for her to be on that
medication would be ethically wrong, and deriving and
implementing intervention thresholds for every single medi-
cation is impractical. It is to avoid this problem and because
treatments with other medications were found to be cost-
effective at their country's currently acceptable WTP thresh-
olds that the National Osteoporosis Guideline Group in the
UK has also recommended utilizing the same intervention
thresholds for these other medications as is used for generic
alendronate despite the formers' higher costs [19, 45].
Access to DXA is relatively easy in Singapore with 16.9
DXA machines available per 1 million population [46], and
thresholds to identify who to send for bone densitometry using
the Osteoporosis Self-Assessment tool for Asians (OSTA)
and/or FRAX® have recently been suggested for Singapore
[47]. The recently published Singapore Osteoporosis
Guidance for primary care, recommends pharmacological in-
tervention in patients with a BMD T-score at any axial site of
≤ − 2.5 and/or a history of a fragility fracture [48]. FRAX®-
based ITs can be considered as an addition to these already
accepted intervention thresholds. If cost-effectiveness is the
sole desired outcome, then fixed MOF and HF ITs of 14 and
3.5% should be recommended in all Singaporean women aged
50 and above. When these ITs were applied on a cohort of
1056 post-menopausal community dwelling Singaporean
women recruited for an assessment threshold study [47], it
was seen that 17% of women above the age of 50 would
qualify for treatment. An alternative approach that would be
still cost-effective would be to recommend age-dependent
thresholds in women 65 years and above, and in those below
the age of 65 years, MOF and HF ITs of 14% and 3.5%,
respectively. With this latter strategy, approximately 27% of
women 65 years and older and 6% of women below the age of
65 years would be eligible for treatment. This approach could
Table 3 Sensitivity analysis (lower monitoring costs) on the incremental cost-effectiveness ratio (expressed in costs (SGD) per QALY gained) of
alendronate compared with no treatment at different major osteoporotic fracture (MOF) and hip fracture (HF) intervention thresholds (ITs) in Singapore
MOF ITs HF ITs
Years Alendronate
Full Adherence














Costs (SGD) per 
QALY gained
50 years 240,227 260,906 118,110 162,417
55 years 134,364 219,248 69,567 102,333
60 years 47, 324 70,263 33,819 42,207
65 years 20,677 31,881 15,571 23,918
70 years 6,771 12,145 4,468 9,039
75 years 3,753 11,745 Cost-saving Cost-saving
80 years Cost-saving 2,583 Cost-saving Cost-saving
Colour code: white, cost-saving (therapy costs lower than saved fracture costs due to drug effectiveness); light grey, below cost-effectiveness threshold
(SD 62,500/QALY gained); dark grey, not cost-effective (i.e. above cost-effectiveness threshold)
The exchange rate between SGD and USD is 1 USD equals 0.71 SGD as of April 30, 2020
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also potentially avoid unnecessary treatment of younger indi-
viduals who are likely to be at lower fracture risk while
directing treatment to older individuals who are at higher risk.
Whether to employ a completely FRAX®-based interven-
tion threshold approach or to consider them as an addition to
existing intervention strategies in Singapore is a matter that
should be gravely discussed at a healthcare policy decision-
making level before implementation.
It should also be kept in mind that ITs based on cost-
effectiveness analysis should not be the sole modality
employed for decision-making in osteoporosis care. They
should be used in conjunction with other clinical parameters
to afford the best and most appropriate individualized care for
patients.
Our study has some limitations. Some data such as
mortality rates after hip and vertebral fractures, utility
data for osteoporosis and osteoporotic fractures and data
on persistence with oral bisphosphonate therapy were
lacking in Singapore, and therefore, they had to be ob-
tained from studies done elsewhere as described earlier.
Another potential limitation of the study is that we did
not adjust mortality according to baseline fracture prob-
ability and different combinations of risk factors of
FRAX®. The risk factor combinations that yield the
same fracture probability may yield different mortality
effects.
Generic alendronate may be associated with poorer ad-
herence [49] than the branded formulation. However, this
is unlikely to be an issue with our study since we adopted
a very cautious approach by estimating that only 53%,
46%, 37%, and 31% of patients would be persistent to
the medication at 6 months, 1 year, 2 years, and 3 years,
respectively [40], and by including this real-world adher-
ence in our modelling strategy. While not including rela-
tively common side effects of bisphosphonate therapy in
our analysis might be considered as a limitation, it has to
be noted that most economic evaluations of oral
bisphosphonates have not included side effects, consider-
ing they are transient and do not affect quality of life and
costs substantially. A few studies such as the NICE ap-
praisal [37] have incorporated gastrointestinal disorders
associated with oral bisphosphonates in cost-effective
analysis by including additional general practitioner
(GP) consultations and the use of a proton pump inhibitor
and this was found to be connected with additional costs
and a utility loss of 1 month. However, the inclusion of
side effects has been shown to only have a very modest
effect on cost-effectiveness using the lifetime horizon
[50].
Our study has several advantages. It is the first such
study from the only advanced economy in Southeast Asia
[51]. We explored the cost-effectiveness of both age-
dependent FRAX® ITs that have been previously
obtained using a translational approach as well as derived
fixed ITs that are cost-effective at all age ranges between
50 and 80 years. Our study considered real-world adher-
ence with oral bisphosphonate therapy while determining
the cost-effectiveness of ITs. Data on fracture incidences
and osteoporosis and fracture care costs were obtained
from the Singapore Ministry of Health’s comprehensive
databases. This ensured that the data used was nationally
representative, credible and accurate. Ours is also the first
such study on cost-effectiveness of osteoporosis care that
had the close input of the Ministry of Health of a country.
Such a collaboration between healthcare providers and
policymakers enables the co-creation of solutions for
problems in osteoporosis management. Having done the
analysis using FRAX®-based fracture probabilities which
is a very granular approach to estimate fracture risk incor-
porating several risk factors provides a more realistic re-
flection of everyday clinical practice.
Conclusion
Treatment of women with the most frequently prescribed anti-
osteoporosis agent in Singapore, namely, generic alendronate,
is cost-effective at age-dependant FRAX® intervention
thresholds at 65 years and older. Furthermore, identifying
women at any age above 50 years with a 10-year risk of
MOF or HF of 14% or 3.5%, respectively, would lead to
efficient use of healthcare resources. Cost-effective access to
therapy for elderly patients at high fracture probability based
on FRAX® could contribute to reduce the growing burden of
osteoporotic fractures in Singapore.
Acknowledgements The authors would like to gratefully acknowledge
Dr. Hao Ying (Health Services Research Centre, Singapore General
Hospital, Singapore) and Dr. Chin Yun Ann (Osteoporosis and Bone
Metabolism Unit, Department of Endocrinology, Singapore General
Hospital, Singapore) for their help with proof-reading the manuscript.
Funding information The study was funded by an educational grant ap-
proved by Singapore General Hospital, 20 College Road, Singapore
169856.
Compliance with ethical standards
Conflicts of interest None.
Open Access This article is licensed under a Creative Commons
Attribution-NonCommercial 4.0 International License, which permits
any non-commercial use, sharing, adaptation, distribution and reproduc-
tion in anymedium or format, as long as you give appropriate credit to the
original author(s) and the source, provide a link to the Creative Commons
licence, and indicate if changes were made. The images or other third
party material in this article are included in the article's Creative
Commons licence, unless indicated otherwise in a credit line to the ma-
terial. If material is not included in the article's Creative Commons licence
and your intended use is not permitted by statutory regulation or exceeds
142 Osteoporos Int (2021) 32:133–144
the permitted use, you will need to obtain permission directly from the
copyright holder. To view a copy of this licence, visit http://
creativecommons.org/licenses/by-nc/4.0/.
References
1. Odén A, McCloskey EV, Kanis JA, Harvey NC, Johansson H
(2015) Burden of high fracture probability worldwide: secular in-
creases 2010-2040. Osteoporos Int 26(9):2243–2248
2. https://population.un.org/wpp/Publications/Files/WPP2017_
KeyFindings.pdf. Last accessed April 26 2020
3. Cheung CL, Ang SB, Chadha M, Chow ESL, Chung YS, Hew FL,
Jaisamrarn U, Ng H, Takeuchi Y,Wu CH, XiaW, Yu J, Fujiwara S
(2018) An updated hip fracture projection in Asia: the Asian
Federation of Osteoporosis Societies study. Osteoporosis and
sarcopenia 4(1):16–21
4. Mohd-Tahir NA, Li SC (2017) Economic burden of osteoporosis-
related hip fracture in Asia: a systematic review. Osteoporos Int
28(7):2035–2044
5. https://www.singstat.gov.sg/modules/infographics/economy. Last
Accessed December 1 2019
6. Chandran M, Lau TC, Gagnon-Arpin I, Dobrescu A, Li W, Leung
MYM, Patil N, Zhao Z (2019) The health and economic burden of
osteoporotic fractures in Singapore and the potential impact of in-





8. Bliuc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, Center
JR et al (2009) Mortality risk associated with low-trauma osteopo-
rotic fracture and subsequent fracture in men and women. JAMA
301(5):513–521
9. Johnell O, Kanis JA, Odén A, Sernbo I, Redlund-Johnell I,
Petterson C et al (2004) Mortality after osteoporotic fractures.
Osteoporos Int 15(1):38
10. Malhotra R, Bautista MAC, Müller AM, Aw S, Koh GCH, Theng
YL, Hoskins SJ, Wong CH, Miao C, LimWS,Malhotra C, Chan A
(2019) The aging of a young nation: population aging in Singapore.
Gerontologist May 59(3):401–410
11. Kanis JA, Johnell O, Oden A, Jonsson B, De Laet C, Dawson A
et al (2000) Risk of hip fracture according to the World Health
Organization criteria for osteopenia and osteoporosis. Bone 27(5):
585–590
12. Siris ES, Miller PD, Barrett-Connor E, Faulkner KG, Wehren LE,
Abbott TA, Berger ML, Santora AC, Sherwood LM (2001)
Identification and fracture outcomes of undiagnosed low bone min-
eral density in postmenopausal women: results from the National
Osteoporosis Risk Assessment. JAMA 286(22):2815–2822
13. Chandran M (2017) Fracture risk assessment in clinical practice:
why do it? What to do it with? J Clin Densitom 20(3):274–279
14. Kanis JA, Harvey NC, Cooper C, Johansson H, Oden A,
McCloskey EV, Advisory Board of the National Osteoporosis
Guideline Group (2016) A systematic review of intervention
thresholds based on FRAX: a report prepared for the National
Osteoporosis Guideline Group and the International Osteoporosis
Foundation. Archives of Osteoporos 11(1):25
15. Tosteson ANA,Melton LJ, Dawson-Hughes B, Baim S, FavusMJ,
Khosla S et al (2008) Cost-effective osteoporosis treatment thresh-
olds: the United States perspective. Osteoporos Int 19(4):437–447
16. Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F,
Oden A et al (2008) Case finding for the management of
osteoporosis with FRAX–assessment and intervention thresholds
for the UK. Osteoporos Int 19(10):1395–1408
17. Lippuner K, JohanssonH, Borgström F, Kanis JA, Rizzoli R (2012)
Cost-effective intervention thresholds against osteoporotic fractures
based on FRAX® in Switzerland. Osteoporos Int 23(11):2579–
2589
18. Chandran M, McCloskey EV, Thu WPP, Logan S, Hao Y, Tay D
et al (2018) FRAX® based intervention thresholds for management
of osteoporosis in Singaporean women. Arch Osteoporos 13(1):130
19. Compston J, Cooper A, Cooper C, Francis R, Kanis JA, Marsh D,
McCloskey E, Reid DM, Selby P, Wilkins M, National
Osteoporosis Guideline Group (NOGG) (2009) Guidelines for the
diagnosis and management of osteoporosis in postmenopausal
women and men from the age of 50 years in the UK. Maturitas
62(2):105–108
20. MacLean C, Newberry S, Maglione M, McMahon M, Ranganath
V, Suttorp M, Mojica W, Timmer M, Alexander A, McNamara M,
Desai SB, Zhou A, Chen S, Carter J, Tringale C, Valentine D,
Johnsen B, Grossman J (2008) Systematic review: comparative
effectiveness of treatments to prevent fractures in men and women
with low bone density or osteoporosis. Ann Intern Med 148(3):
197–213
21. Hiligsmann M, Ethgen O, Bruyère O, Richy F, Gathon HJ,
Reginster JY et al (2009) Development and validation of a
Markov microsimulation model for the economic evaluation of
treatments in osteoporosis. Value Health 12(5):687–696
22. Hiligsmann M, Williams SA, Fitzpatrick LA, Silverman SS, Weiss
R, Reginster JY et al (2019) Cost-effectiveness of sequential treat-
ment with abaloparatide vs. teriparatide for United States women at
increased risk of fracture. Semin Arthritis Rheum 49(2):184–196
23. Pearce F, Lin L, TeoEl NK, Khoo D (2019) Health technology
assessment and its use in drug policies: Singapore. Value in
Health regional issues 18:176–183
24. Hiligsmann M, Reginster JY, Tosteson ANA, Bukata SV, Saag
KG, Gold DT, Halbout P, Jiwa F, Lewiecki EM, Pinto D, Adachi
JD, al-Daghri N, Bruyère O, Chandran M, Cooper C, Harvey NC,
Einhorn TA, Kanis JA, Kendler DL, Messina OD, Rizzoli R, Si L,
Silverman S (2019) Recommendations for the conduct of economic
evaluations in osteoporosis: outcomes of an experts’ consensus
meeting organized by the European Society for Clinical and
Economic Aspects of Osteoporosis, Osteoarthritis and
Musculoskeletal Diseases (ESCEO) and the US branch of the
International Osteoporosis Foundation. Osteoporos Int 30(1):45–57
25. Yong EL, Ganesan G, Kramer MS, Logan S, Lau TC, Cauley JA,
Tan KB (2019) Hip fractures in Singapore: ethnic differences and
temporal trends in the new millennium. Osteoporos Int 30(4):879–
886
26. Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA 3rd, Berger
M (2000) Patients with prior fractures have an increased risk of
future fractures; a summary of the literature and statistical synthesis.
J Bone Miner Res 15:721–739
27. Kanis JA, Johnell O, De Laet C et al (2004) A meta-analysis of
previous fracture and subsequent fracture risk. Bone35:375–382
28. Johnell O, Kanis JA, Oden A et al (2004) Fracture risk following an
osteoporotic fracture. Osteoporos Int 15:175–179
29. DOS mortality rates. https://singstat.gov.sg/publicfacing/
createDataTable.action?refid=13249 Last Accessed 1 Dec 2019
30. Parker MJ, Anand JK (1991) What is the true mortality of hip
fracture? Public Health 105:443–446
31. SvedbomA, Borgstöm F, Hernlund E, StrömO, Alekna V, Bianchi
ML, Clark P, Curiel MD, Dimai HP, Jürisson M, Kallikorm R,
Lember M, Lesnyak O, McCloskey E, Sanders KM, Silverman S,
Solodovnikov A, Tamulaitiene M, Thomas T, Toroptsova N,
Uusküla A, Tosteson ANA, Jönsson B, Kanis JA (2018) Quality
of life for up to 18months after low-energy hip, vertebral, and distal
143Osteoporos Int (2021) 32:133–144
forearm fractures-results from the ICUROS. Osteoporos Int 29(3):
557–566
32. Hiligsmann M, Ethgen O, Richy F, Reginster JY (2008) Utility
values associated with osteoporotic fracture: a systematic review
of the literature. Calcif Tissue Int 82(4):288–292
33. Hanmer J, Lawrence WF, Anderson JP, Kaplan RM, Fryback DG
(2006) Report of nationally representative values for the noninsti-
tutionalized US adult population for 7 health-related quality-of-life
scores. Med Decis Mak 26(4):391–400
34. Wade SW, Satram-Hoang S, Nadkar A, Macarios D, Tosteson
ANA (2011) Impact of medication adherence on health care utili-
zation and productivity: self-reported data from a cohort of post-
menopausal women on osteoporosis therapy. Clin Ther 33(12):
2006–2015
35. Cheen MH, Kong MC, Zhang RF, Tee FM, Chandran M (2012)
Adherence to osteoporosis medications amongst Singaporean pa-
tients. Osteoporos Int Mar 23(3):1053–1060
36. Hiligsmann M, Boonen A, Rabenda V, Reginster JY (2012) The
importance of integrating medication adherence into
pharmacoeconomic analyses: the example of osteoporosis. Expert
review of pharmacoeconomics & outcomes research 12(2):159–
166
37. National Institute for Health and Clinical Excellence (NICE).
Systematic reviews of clinical effectiveness prepared for the guide-
line “Osteoporosis assessment of fracture risk and the prevention of
osteoporotic fractures in individuals at high risk https://www.nice.
org.uk/guidance/ta464/chapter/3-Committee-discussion#clinical-
effectiveness Last accessed December 1 2019
38. HiligsmannM, Evers SM, Ben SedrineW, Kanis JA, Ramaekers B,
Reginster JY, Silverman S,Wyers CE, Boonen A (2015) A system-
atic review of cost-effectiveness analyses of drugs for postmeno-
pausal osteoporosis. Pharmacoeconomics 33(3):205–224
39. Ström O, Landfeldt E, Garellick G (2015) Residual effect after oral
bisphosphonate treatment and healthy adherer effects–the Swedish
Adherence Register Analysis (SARA). Osteoporos Int 26(1):315–
325
40. Hiligsmann M, McGowan B, Bennett K, Barry M, Reginster JY
(2012) The clinical and economic burden of poor adherence and
persistence with osteoporosis medications in Ireland. Value Health
15(5):604–612
41. Fatoye F, Smith P, Gebrye T, Yeowell G (2019) Real-world per-
sistence and adherence with oral bisphosphonates for osteoporosis:
a systematic review. BMJ Open 9(4):e027049
42. World Health Organization. CHOosing Interventions that are Cost
Effective (WHO-CHOICE): cost effectiveness thresholds. http://
www.who.int/choice/costs/CER_thresholds/en/ Last accessed
December 1 2019
43. Chan DC, McCloskey EV, Chang CB, Lin KP, Lim LC, Tsai KS,
Yang RS (2017) Establishing and evaluating FRAX® probability
thresholds in Taiwan. J Formos Med Assoc Mar 116(3):161–168
44. Harvey NC, McCloskey E, Kanis JA, Compston J, Cooper C
(2017) Bisphosphonates in osteoporosis: NICE and easy? Lancet
390(10109):2243–2244
45. Kanis JA, McCloskey E, Johnson B, Cooper A, Strom O,
Borgstrom F (2010) An evaluation of the NICE guidance for the
prevention of osteoporotic fragility fractures in postmenopausal
women. Archives of Osteoporosis 5:19–48
46. https://iofbonehealth.org/data-publications/regionalaudits/asia-
pacific-regionalaudit. Last accessed April 26 2020
47. Chandran M, Chin YA, Choo KS, Ang WC et al (2020)
Comparison of the osteoporosis self-assessment tool for Asians
and the fracture risk assessment tool - FRAX to identify densito-
metric defined osteoporosis: aA discriminatory value analysis in a
multi-ethnic female population in Southeast Asia. Osteoporosis
and Sarcopenia. https://doi.org/10.1016/j.afos.2020.04.001
48. Chandran M, Ang SB, Au L, et al. (2018) Appropriate care guide:
osteoporosis identification and management in primary care.
Singapore: Ministry of Health. http://www.ace-hta.gov.sg/our-
guidance/osteoporosis-identification-and-management-in-primary-
care.html. Last accessed April 26 2020
49. Kanis JA, Reginster JY, Kaufman JM, Ringe JD, Adachi JD,
HiligsmannM,Rizzoli R, Cooper C (2012) A reappraisal of generic
bisphosphonates in osteoporosis. Osteoporos Int 23(1):213–221
50. Kanis JA, Adams J, Borgstrom F, Cooper C, Johnson B, Preedy D,
Selby P, Compston J (2007) The cost-effectiveness of alendronate
in the management of osteoporosis. Bone 42(1):4–115
51. https://southeastasiaglobe.com/how-southeast-asian-countries-
compare-growth-development/. Last accessed April 26 2020
Publisher’s note Springer Nature remains neutral with regard to jurisdic-
tional claims in published maps and institutional affiliations.
144 Osteoporos Int (2021) 32:133–144
